Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, discusses this prospective study of endocrine therapy alone in patients with ER-positive, HER2-negative, node-negative breast cancer (Abstract 5BA).
Federico Cappuzzo, MD, of Istituto Toscano Tumori-Ospedale Civile Livorno, and Tony Mok, MD, of The Chinese University of Hong Kong, discuss current strategies for treating patients with acquired resistance, and what the future holds for these patients.
Mary K. Gospodarowicz, MD, of Princess Margaret Hospital, discusses the work of the Global Task Force on Radiotherapy for Cancer Control and its efforts to improve access to vital radiation treatment worldwide, especially in low- and middle-income countries.
Benjamin Besse, MD, PhD, of the Institut Gustave Roussy, and Tony Mok, MD, of The Chinese University of Hong Kong, discuss this phase II trial of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1–selected NSCLC (Abstract 17LBA).
Priscilla K. Brastianos, MD, of Massachusetts General Hospital, discusses genomic characterization of brain metastases and paired primary tumors, which could reveal potential therapeutic targets (Abstract 2905).
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, summarizes his educational lecture on obesity, inflammation, and cancer—an important topic in oncology.
